Roivant Sciences
We have worked to ensure an open, diverse, and inclusive culture, while building a leadership team, board of directors and broader employee base that reflects these values. Our Vants have conducted 12 positive Phase 3 trials since 2019, and launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults In 2022, we launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults. Organon acquired Dermavant in 2024 Pipeline Advancing
Basic Information
- Category: Immunology
- Founded: 2019
- Headquarters: New York, NY
- Website: roivant.com
Documented Facts
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: D0 (No linked source recorded for this statement.)
- Stock ticker: ROIV (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Roivant Sciences — Official Site (official)
- Roivant Sciences on linkedin (social)
- Roivant Sciences Ltd. — SEC EDGAR (reference)
Citation Guidance
Explore Immunology profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Roivant Sciences.
- Canonical profile: https://brandsource.ai/brands/roivant-sciences
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/roivant-sciences/json-ld
- Citation profile API: https://brandsource.ai/api/brands/roivant-sciences/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-27T08:35:03.630Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
We have worked to ensure an open, diverse, and inclusive culture, while building a leadership team, board of directors and broader employee base that reflects these values. Our Vants have conducted 12 positive Phase 3 trials since 2019, and launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults In 2022, we launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults. Organon acquired Dermavant in 2024 Pipeline Advancing
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.